Journal article
Incidence of Diabetes Following Ramipril or Rosiglitazone Withdrawal
Abstract
OBJECTIVE: To examine the impact of withdrawing rosiglitazone and ramipril medication on diabetes incidence after closeout of the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) trial.
RESEARCH DESIGN AND METHODS: The 3,366 DREAM subjects at trial end who had not developed diabetes while taking double-blind study medication were transferred to single-blind placebo for 2 to 3 months before undergoing an oral …
Authors
Investigators TDT
Journal
Diabetes Care, Vol. 34, No. 6, pp. 1265–1269
Publisher
American Diabetes Association
Publication Date
June 1, 2011
DOI
10.2337/dc10-1567
ISSN
0149-5992